Sub F1 C1

1. (Twice Amended) A tablet comprising crystals of a pharmaceutically acceptable salt of citalopram, wherein the median particle size of the crystals is at least 40 μm, which is prepared by direct compression of the pharmaceutically acceptable salt and pharmaceutically acceptable excipients.

2 ~~4.~~ (Twice Amended) The tablet according to claim 1 which does not contain a binder.

Sub F1

3 ~~5.~~ (Twice Amended) The tablet according to claim 1 which contains 2-60% w/w active ingredient calculated as citalopram base.

4 ~~6.~~ (Twice Amended) The tablet according to claim 1 which contains a filler selected from lactose, sugars, calcium phosphates, starch, modified starches, microcrystalline cellulose, calcium sulfate and calcium carbonate.

C2

5 ~~7.~~ (Twice Amended) The tablet according to claim 4 ~~6~~, wherein the filler is a microcrystalline cellulose.

6 ~~8.~~ (Twice Amended) The tablet according to claim 1 which contains a lubricant selected from metallic stearates, stearic acid, wax, hydrogenated vegetable oil, talc and colloidal silica.

24

C

Sub F1 cont.

7 ~~9.~~ (Twice Amended) The tablet according to claim ~~8~~ 6, wherein the lubricant is magnesium stearate or calcium stearate.

C2 cont

8 ~~10.~~ (Twice Amended) The tablet according to claim 1 which is substantially free of lactose.

Sub F1

9 ~~12.~~ (Twice Amended) The tablet according to claim 1 wherein the pharmaceutically acceptable salt is citalopram hydrobromide or citalopram hydrochloride.

C3

10 ~~13.~~ (Twice Amended) The tablet according to claim ~~12~~ 9, wherein the pharmaceutically acceptable salt is citalopram hydrobromide.

15 ~~20.~~ (Twice Amended) Method for manufacture of crystals of a pharmaceutically acceptable salt of citalopram having a median particle size of at least 40μm, said method comprising the steps of forming a solution of a pharmaceutically acceptable salt of citalopram in a solvent system at a first temperature, cooling the solution to a second temperature, seeding the solution by addition of crystals of said citalopram salt, followed by holding the solution at said second temperature and a controlled cooling the solution down to a third temperature, and isolating said crystals.

C4

17 ~~22.~~ (Twice Amended) The ~~method~~ according to claim ~~20~~ 15, wherein the pharmaceutically acceptable salt of citalopram is citalopram hydrobromide or citalopram hydrochloride.

C5

25

C

C5

18 ~~23.~~ (Twice Amended) The method according to claim 17, wherein the pharmaceutically acceptable salt of citalopram is citalopram hydrobromide.

C6

25 ~~30.~~ (Twice Amended) The method according to claim 15 wherein the step of holding the solution at said second temperature is from 30 minutes to 7 days .

C7

28 ~~33.~~ (Twice Amended) The method according to claim 15 wherein the step of isolating the crystals of a pharmaceutically acceptable salt of citalopram is performed by filtration.

Sub F1

29 ~~36.~~ (Amended) The tablet of claim 1, which contains 10-40% w/w active ingredient calculated as citalopram base.

C8

30 ~~37.~~ (Amended) The tablet of claim 1, which contains 15-25% w/w active ingredient calculated as citalopram base.

31 ~~38.~~ (Amended) The tablet of claim 4, wherein said filler is a sugar selected from the group consisting of sorbitol, mannitol, dextrose and sucrose.

32 ~~39.~~ (Amended) The tablet of claim 4, wherein said filler is a calcium phosphate selected from the group consisting of dibasic, tribasic, hydrous and anhydrous calcium phosphate.

26

C

33 ~~40.~~ (Amended) The tablet of claim ~~8~~ 6, wherein said lubricant is a metallic stearate selected from the group consisting of magnesium, calcium and sodium stearate.

34 ~~41.~~ (Amended) The tablet of claim 1, wherein the crystals have a median particle size of 40-200μm.

35 ~~42.~~ (Amended) The tablet of claim 1, wherein the crystals have a median particle size of 45-150μm.

36 ~~43.~~ (Amended) The tablet of claim 1, wherein the crystals have a median particle size of 50-100μm.

48 ~~55.~~ (Amended) The method according to claim ~~30~~ 25, wherein the step of holding the solution at said second temperature is from 1 hour to 4 days.

49 ~~56.~~ (Amended) The method according to claim ~~30~~ 25, wherein the step of holding the solution at said second temperature is from 12 to 36 hours.